hear the news

Covid 19 Nasal Vaccine: After giving anti-corona vaccine through muscles to prevent infection, now the nasal vaccine has been started. More than 100 pharma companies in different countries are involved in the study and production of Nasal Vaccine.

According to experts, in the coming times, nasal technology can prove to be helpful against not only corona, but also other types of infectious diseases. This technique not only develops antibodies in people but is also helpful in preventing the spread of infection.

Dr. Sanjay Bagai, Chairman of Nephron Clinic, says that pharma companies also hope that with the help of this technology, mild cases of infection can be stopped and its spread can also be brought under control. This is known as sterilizing immunity. Some mucosal vaccines are already approved for other diseases, including a sprayable vaccine against influenza.

Currently injectable vaccine is more effective
According to experts, at present the anti-corona vaccine given through muscle is showing much better results. Senior Dr. Amit Kumar of RML Hospital in New Delhi says that one reason for this is to inject the vaccine into the muscles. They reported that intra-muscular shots indicate an immune response, which involves T cells. This allows the drug to reach the cells directly.

20 vaccines reach trial
According to London-based health analytics company Air Finity, around 20 nasal vaccines have so far reached trials worldwide, four of which have completed a third study in India and Iran and two in China. Some are still in testing condition.

Also effective as a precautionary dose

  • The nasal vaccine Inkovac is up to 94 percent effective even as a precautionary dose. This vaccine will be available in all centers, private and government. Production will take place in Gujarat, Karnataka, Maharashtra and Telangana. Its storage is also easy. Can be kept at 2 to 8 °C.
  • The vaccine was studied on more than four thousand people in 14 hospitals across the country.
  • It has been developed on chimpanzee adenovirus vector technology and is an improved version of Covaxin.
  • This vaccine stops the virus in the upper respiratory tract itself. This is the 15th vaccine in the country.

The world’s first such vaccine
This is not only India’s but the world’s first intranasal vaccine. It will prove to be a game changer globally. Not only corona, this technology can also deal with future infectious diseases. -Doctor. Krishna Ella, Bharat Biotech

Expansion

Covid 19 Nasal Vaccine: After giving anti-corona vaccine through muscles to prevent infection, now the nasal vaccine has been started. More than 100 pharma companies in different countries are involved in the study and production of Nasal Vaccine.

According to experts, in the coming times, nasal technology can prove to be helpful against not only corona, but also other types of infectious diseases. This technique not only develops antibodies in people but is also helpful in preventing the spread of infection.

Dr. Sanjay Bagai, Chairman of Nephron Clinic, says that pharma companies also hope that with the help of this technology, mild cases of infection can be stopped and its spread can also be brought under control. This is known as sterilizing immunity. Some mucosal vaccines are already approved for other diseases, including a sprayable vaccine against influenza.

Currently injectable vaccine is more effective

According to experts, at present the anti-corona vaccine given through muscle is showing much better results. Senior Dr. Amit Kumar of RML Hospital in New Delhi says that one reason for this is to inject the vaccine into the muscles. He explained that intra-muscular shots indicate an immune response, which involves T cells. This allows the drug to reach the cells directly.

20 vaccines reach trial

According to London-based health analytics company Air Finity, around 20 nasal vaccines have so far reached trials worldwide, four of which have completed a third study in India and Iran and two in China. Some are still in testing condition.

Also effective as a precautionary dose

  • The nasal vaccine Inkovac is up to 94 percent effective even as a precautionary dose. This vaccine will be available in all centers, private and government. Production will take place in Gujarat, Karnataka, Maharashtra and Telangana. Its storage is also easy. Can be kept at 2 to 8 °C.
  • The vaccine was studied on more than four thousand people in 14 hospitals across the country.
  • It has been developed on chimpanzee adenovirus vector technology and is an improved version of Covaxin.
  • This vaccine stops the virus in the upper respiratory tract itself. This is the 15th vaccine in the country.

The world’s first such vaccine

This is not only India but the world’s first intranasal vaccine. It will prove to be a game changer globally. Not only corona, this technology can also deal with future infectious diseases. -Doctor. Krishna Ella, Bharat Biotech

,

By admin

Leave a Reply

Your email address will not be published.